Alvotech Entered into an Exclusive License Agreement with BiosanaPharma to Co-Develop AVT23, a Proposed Biosimilar to Xolair (omalizumab)
Shots:
- BiosanaPharma is eligible to receive an up front & will also be eligible for royalties. Additionally, Alvotech to get exclusive global rights for AVT23, a proposed biosimilar to Xolair
- The companies will jointly develop AVT23 which is currently in late-stage development. BiosanaPharma is reporting the completion of a PK study that showed that AVT23’s bioavailability, safety, tolerability, and immunogenicity were comparable to Xolair
- On Dec 7, 2021, Alvotech had entered into a definitive business combination agreement with Oaktree where combined company’s securities are expected to be traded on NASDAQ under the ticker “ALVO”, upon the closing of the transaction
Ref: Alvotech | Image: Alvotech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com